StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.46−0.06 (-1.70%)

Close on Nov 17, 2026Market cap $224.08MP/E –Yield –

Immuneering operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Immuneering's operating income for the twelve months ending Sep 30, 2026 was -$73.88M. For fiscal 2025 it was -$59.38M. The highest annual figure on record is -$17.08M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$59.38M–
FY2024Dec 31, 2024-$64.07M–
FY2023Dec 31, 2023-$58.41M–
FY2022Dec 31, 2022-$51.74M–
FY2021Dec 31, 2021-$33.89M–
FY2020Dec 31, 2020-$17.08M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$25.79M–
Q2 FY2026Jun 30, 2026-$19.00M–
Q1 FY2026Mar 31, 2026-$15.34M–
Q4 FY2025Dec 31, 2025-$13.75M–
Q3 FY2025Sep 30, 2025-$15.38M–
Q2 FY2025Jun 30, 2025-$14.76M–
Q1 FY2025Mar 31, 2025-$15.48M–
Q4 FY2024Dec 31, 2024-$18.56M–
Q3 FY2024Sep 30, 2024-$15.27M–
Q2 FY2024Jun 30, 2024-$14.91M–
Q1 FY2024Mar 31, 2024-$15.33M–
Q4 FY2023Dec 31, 2023-$16.30M–
Q3 FY2023Sep 30, 2023-$13.93M–
Q2 FY2023Jun 30, 2023-$13.50M–
Q1 FY2023Mar 31, 2023-$14.68M–
Q4 FY2022Dec 31, 2022-$13.99M–
Q3 FY2022Sep 30, 2022-$13.19M–
Q2 FY2022Jun 30, 2022-$11.65M–
Q1 FY2022Mar 31, 2022-$12.93M–
Q4 FY2021Dec 31, 2021-$11.12M–
Q3 FY2021Sep 30, 2021-$8.54M–
Q2 FY2021Jun 30, 2021-$7.99M–
Q1 FY2021Mar 31, 2021-$6.24M–
Q4 FY2020Dec 31, 2020-$5.84M–
Q3 FY2020Sep 30, 2020-$4.40M–
Q2 FY2020Jun 30, 2020-$3.61M–

More Immuneering figures

See a number that looks wrong?